RAFFA WEALTH MANAGEMENT, LLC’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$152 Hold
9
﹤0.01% 1306
2026
Q1
$115 Hold
9
﹤0.01% 1270
2025
Q4
$81 Hold
9
﹤0.01% 1151
2025
Q3
$155 Hold
9
﹤0.01% 1154
2025
Q2
$84 Hold
9
﹤0.01% 1090
2025
Q1
$64 Hold
9
﹤0.01% 1065
2024
Q4
$105 Hold
9
﹤0.01% 1096
2024
Q3
$185 Hold
9
﹤0.01% 1056
2024
Q2
$201 Hold
9
﹤0.01% 1118
2024
Q1
$248 Sell
9
-159
-95% -$4.42K ﹤0.01% 1093
2023
Q4
$5.12K Buy
168
+159
+1,767% +$4.57K ﹤0.01% 387
2023
Q3
$285 Hold
9
﹤0.01% 1004
2023
Q2
$367 Hold
9
﹤0.01% 998
2023
Q1
$335 Hold
9
﹤0.01% 1003
2022
Q4
$314 Hold
9
﹤0.01% 998
2022
Q3
$504 Hold
9
﹤0.01% 1032
2022
Q2
$466 Sell
9
-2
-18% -$102 ﹤0.01% 1033
2022
Q1
$799 Hold
11
﹤0.01% 937
2021
Q4
$1.3K Hold
11
﹤0.01% 786
2021
Q3
$1.48K Buy
11
+9
+450% +$1.36K ﹤0.01% 697
2021
Q2
$324 Hold
2
﹤0.01% 1077
2021
Q1
$161 Hold
2
﹤0.01% 1088
2020
Q4
$109 Buy
+2
New +$73 ﹤0.01% 903

Other funds holding NTLA

RAFFA WEALTH MANAGEMENT, LLC's NTLA Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 9 shares worth $152. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in NTLA in Q4 2020 and has held it in 23 quarters since. The position peaked at $5.12K in Q4 2023. 71 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • RAFFA WEALTH MANAGEMENT, LLC held 9 shares of Intellia Therapeutics worth $152 as of Q2 2026.
  • RAFFA WEALTH MANAGEMENT, LLC left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #1306 holding.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • RAFFA WEALTH MANAGEMENT, LLC's Intellia Therapeutics position peaked at $5.12K in Q4 2023.
  • 71 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.